Although advances in therapy for HER2-positive breast-cancer patients have led to significant increases in OS and PFS rates, the increasing incidence of acquired resistance to current anti-HER2 directed therapies remains a problem for HER2-positive advanced breast cancer [3]. Here, ERBB2 is linked to breast cancer.